{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:41:10Z","timestamp":1780461670059,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jval.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T20:03:46Z","timestamp":1558037026000},"page":"777-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Meng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bennette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2019.02.002_bib1","series-title":"The Value of Life Near Its End And Terminal Care","author":"Becker","year":"2007"},{"issue":"2","key":"10.1016\/j.jval.2019.02.002_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force Report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.02.002_bib3","series-title":"Terminal Care and the Value of Life Near its End","author":"Philipson","year":"2010"},{"key":"10.1016\/j.jval.2019.02.002_bib4","first-page":"265","article-title":"The option value of innovative treatments in the context of chronic myloid leukemia","volume":"18","author":"Sanchez","year":"2012","journal-title":"Am J Manag Care"},{"issue":"10","key":"10.1016\/j.jval.2019.02.002_bib5","first-page":"e340","article-title":"The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma","volume":"23","author":"Thornton Snider","year":"2017","journal-title":"Am J Manag Care"},{"issue":"26","key":"10.1016\/j.jval.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2019.02.002_bib7","first-page":"2251","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"362","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jval.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.jval.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9839","key":"10.1016\/j.jval.2019.02.002_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jval.2019.02.002_bib13","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jval.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2019.02.002_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2019.02.002_bib17","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2014), released April 2017, based on the November 2016 submission."},{"issue":"5","key":"10.1016\/j.jval.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cpt.194","article-title":"A\u00a0tool for predicting regulatory approval after phase II testing of new oncology compounds","volume":"98","author":"DiMasi","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jval.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/clpt.2013.117","article-title":"Clinical approval success rates for investigational cancer drugs","volume":"94","author":"DiMasi","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J\u00a0Health Econ"},{"issue":"8","key":"10.1016\/j.jval.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jval.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.jval.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jval.2019.02.002_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2019.02.002_bib25","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jval.2019.02.002_bib26","first-page":"202","article-title":"Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis","volume":"16","author":"Barzey","year":"2013","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2019.02.002_bib27","author":"AnalySource"},{"issue":"1","key":"10.1016\/j.jval.2019.02.002_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J\u00a0Econ Perspect"},{"key":"10.1016\/j.jval.2019.02.002_bib29","author":"Centers for Medicare & Medicaid Services"},{"issue":"18","key":"10.1016\/j.jval.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2016.71.9716","article-title":"Economic burden of chronic conditions among survivors of cancer in the United States","volume":"35","author":"Guy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"5 Pt 1","key":"10.1016\/j.jval.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0190-9622(98)70195-1","article-title":"An estimate of the annual direct cost of treating cutaneous melanoma","volume":"38","author":"Tsao","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2019.02.002_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archdermatol.2009.389","article-title":"Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)\u2014Medicare data","volume":"146","author":"Seidler","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jval.2019.02.002_bib33","first-page":"173","article-title":"Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jval.2019.02.002_bib34","series-title":"Cost Driver of Cancer Care: A Retrospective Analysis of Medicare and Commercially Insured Population Claim Data 2004-2014, Milliman","author":"Fitch","year":"2016"},{"issue":"3","key":"10.1016\/j.jval.2019.02.002_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6605187","article-title":"Societal preference values for advanced melanoma health states in the United Kingdom and Australia","volume":"101","author":"Beusterien","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jval.2019.02.002_bib36","author":"Bureau of Labor Statistics"},{"key":"10.1016\/j.jval.2019.02.002_bib37","series-title":"Final value assessment framework for 2017-2019","year":"2017"},{"issue":"36","key":"10.1016\/j.jval.2019.02.002_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgj004","article-title":"Competing risks to breast cancer mortality","volume":"53706","author":"Rosenberg","year":"2006","journal-title":"J\u00a0Natl Cancer Inst Monogr"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519301159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519301159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:15:40Z","timestamp":1761095740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301519301159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1098301519301159"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.02.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}